What is Solventum's gross profit margin?

What factors drove the changes in Solventum's revenue and profit?

What were the key takeaways from Solventum’s earnings call?

What guidance did Solventum's management provide for the next earnings period?

What were the key takeaways from Solventum's earnings call?

What does Solventum do and what are its main business segments?

Did Solventum beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Solventum next quarter?

- **Revenue Growth**: 3.5% 2025 organic growth, guided to 2-3% in 2026, driven by MedSurg (Acera integration), Dental (new products), and HIS (autonomous coding). 
- **Margin Expansion**: 21-21.5% 2026 operating margin target (vs. 20.5% in 2025), supported by $500M Transform for the Future savings. 
- **Share Buyback**: $1B program launched in Q1 2026 to offset dilution. 
- **Tariff Risk**: $100M-$120M 2026 impact, partially offset by SKU rationalization. 
- **Long-Range Plan**: On track for 4-5% revenue growth, 23-25% margins, and 10% EPS CAGR by 2028.

**【CEO Summary Section】**
- **2025 Year in Review**: Achieved 3.3% organic sales growth, exceeding expectations, driven by new product launches, sales force restructuring, and portfolio optimization (e.g., Acera Surgical acquisition). 
- **Segment Performance**: 
  - **MedSurg**: Advanced Wound Care grew 1.7% (V.A.C. Peel & Place, Acera integration), Infection Prevention & Surgical Solutions up 4.2% (Tegaderm CHG adoption). 
  - **Dental Solutions**: 5.9% growth (back order resolution, ClinPro Clear, Filtek Easy Match). 
  - **HIS**: 3.2% growth (autonomous coding adoption, 360 Encompass expansion). 
- **Strategic Initiatives**: $1B share repurchase program launched in Q1 2026; Transform for the Future program targeting $500M cost savings by 2030. 
- **Long-Range Plan**: On track to accelerate to 4-5% revenue growth, 23-25% operating margins, and 10% EPS CAGR. 

**【CFO Financial Commentary】**
- **Q4 2025 Results**: 
  - **Revenue**: $2B (3.5% organic growth, 3.7% reported decline due to P&F divestiture). 
  - **Margins**: 19.9% operating margin (53.5% gross margin, 16.6% tax rate). 
  - **Cash Flow**: Negative $10M free cash flow (excluding one-time costs). 
- **2026 Guidance**: 
  - **Sales**: 2-3% organic growth (3-4% ex-SKU exits). 
  - **Margins**: 21-21.5% operating margin (50-100bps expansion vs. 2025). 
  - **EPS**: $6.40-$6.60 (vs. $6.11 in 2025). 
  - **Free Cash Flow**: $200M (excluding separation costs). 
- **Key Risks**: $100M-$120M tariff impact, 100bps SKU exit drag. 

**【Q&A Highlights】**
- **Margins & Tariffs**: Q4 gross margin headwinds ($150M one-time costs) expected to ease; 2026 tariffs could add $100M expense. 
- **AI in HIS**: Autonomous coding leadership (1M+ proprietary rules, 80%+ acceptance rates) positions for growth. 
- **Dental Momentum**: 6% Q4 growth driven by new products; normalized 3-4% growth expected. 
- **M&A Strategy**: Tuck-in acquisitions (e.g., Acera) to accelerate MedSurg growth; $1B buyback to offset dilution. 
- **Separation Progress**: 90% TSAs to exit by end-2026; 2027 focus on rebranding and supply chain independence.

Solventum Corporation (SOLV) Q4 2025 Earnings Call Transcript

- **Q3 Beat & Guidance Raise**: Organic sales +2.7%, EPS $1.50 (vs. $1.45 est.), with full-year EPS guidance increased to $5.98-$6.08.
- **Transform for the Future**: $500M 4-year cost-saving program to offset tariffs, enabling $1B+ M&A and potential capital returns.
- **Business Momentum**: Advanced Wound Care +2.7%, Dental Solutions +6.5% organically; HIS segment up 5.6% on RCM software strength.
- **Balance Sheet Strength**: $1.6B cash post-P&F sale, $2.7B debt reduction, and credit upgrades.
- **Tariff Mitigation**: $60M-$80M annual headwind, partially offset by $500M programmatic savings.

**【CEO Summary Section】**
- Delivered strong Q3 performance, raising full-year sales and EPS guidance due to faster-than-expected progress toward long-range plan (LRP) targets.
- Highlighted three key drivers: successful ERP implementation, commercial restructuring (e.g., 1,000+ position shifts), and revitalized innovation pipeline (doubling vitality index).
- Advanced Wound Care grew 2.7% organically, driven by Prevena single-use devices; Dental Solutions saw 6.5% organic growth due to new product launches and service level improvements.
- Announced Transform for the Future initiative: a 4-year, $500M cost-saving program to offset tariffs and support LRP margin targets, while enabling M&A and potential capital returns.
- Emphasized portfolio optimization, with 60% completion of SKU rationalization and successful sale of Purification & Filtration business, reducing debt and improving leverage.

**【CFO Financial Commentary】**
- Q3 2025 sales: $2.1B (2.7% organic growth), EPS: $1.50 (vs. $1.45 estimate), driven by volume growth and tariff mitigation.
- Updated full-year guidance: organic sales growth at high end of 2.5%-3.5% range, EPS: $5.98-$6.08 (up from $5.88-$6.03).
- Gross margin: 55.8% (down 20bps due to tariffs), operating margin: 20.6% (in line with expectations).
- Free cash flow: $735M year-to-date (93% conversion), with updated 2025 guidance of $150M-$250M (excluding P&F impacts).
- Transform for the Future program to deliver $500M annual savings by 2029, offsetting $60M-$80M annual tariff headwinds.

**【Q&A Key Highlights】**
- **Transform for the Future**: CEO Bryan Hanson clarified it was always part of the transformation plan but delayed until post-P&F sale; CFO Wayde McMillan noted $500M cost over 4 years, with savings reinvested in R&D and commercial infrastructure.
- **Dental Growth Sustainability**: CEO emphasized new product launches (e.g., Filtek Composite Warmer) and specialized sales teams, with no extraordinary pricing impact.
- **Tariff Visibility**: CFO maintained $60M-$80M annual headwind estimate, citing dynamic trade environment.
- **2026 Outlook**: CEO indicated faster-than-expected LRP progress, with 4%-5% sales growth target achievable; CFO highlighted no tougher comps next year.
- **M&A Strategy**: CEO announced focus on $1B+ tuck-in acquisitions in existing markets, with first deals possible in 2026.


Solventum Corporation (SOLV) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 organic +2.8%, raising FY25 guidance to 2-3% (prev. 1.5-2.5%).
- **EPS Beat**: $1.69 vs. $1.50-1.60, driving FY25 EPS to $5.80-5.95 (prev. $5.45-5.65).
- **MedSurg Momentum**: 3.9% growth from specialized sales and new products; H2 acceleration expected in Advanced Wound Care.
- **Tariff Mitigation**: Impact reduced to $60-80M (prev. $80-100M), easing margin pressure.
- **P&F Deal**: Expected close by year-end with $0.25-0.30 EPS accretion, positioning for debt deleverage and M&A.
- **Free Cash Flow**: Guiding to $450-550M, with 2026+ improvement as separation costs decline.


**【CEO Opening Remarks】**
- Delivered another solid quarter with strong execution, raising 2025 sales growth and EPS guidance.
- Confident in achieving long-range plan targets (4-5% sales growth, 10% EPS CAGR) due to differentiated brands, cultural enhancements, and disciplined M&A strategy.
- Highlighted progress in ERP implementation, tariff mitigation, and P&F transaction (now expected to close by year-end with $0.25-0.30 EPS accretion).
- Recognized as a Fortune 500 company and top workplace, reflecting team dedication and values-driven culture.

**【CEO Business Segment Updates】**
- **MedSurg**: 3.9% organic growth driven by Infection Prevention & Surgical Solutions (5.9%), despite recall-related headwinds in Advanced Wound Care. Peel & Place launch in Europe and new NPWT customers boost confidence for H2 acceleration.
- **Dental Solutions**: 0.7% growth from new product launches (Clinpro Clear, Filtek Easy Match) and Clarity aligners, offsetting market challenges.
- **Health Information Systems**: 3.2% growth from 360 Encompass adoption (Australia, Middle East) and Ensemble partnership for autonomous coding.
- **Purification & Filtration**: 3.1% growth from bioprocessing and industrial filtration, with P&F transaction simplifying operations.

**【CFO Financial Commentary】**
- Q2 sales: $2.2B (+2.8% organic, +3.9% reported), driven by volume and new products. FX +110bps, SKU exits -60bps.
- **Gross Margin**: 56.0% (20bps YoY improvement), benefiting from sales mix and programmatic savings.
- **Operating Expenses**: $736M (+2% YoY), offset by $120M restructuring savings.
- **EPS**: $1.69 (vs. guidance $1.50-1.60), driven by sales outperformance and tax benefits.
- **Free Cash Flow**: $59M (Q2), guiding to $450-550M for FY25 (impacted by separation costs).
- **Updated Guidance**: Organic sales 2-3% (prev. 1.5-2.5%), EPS $5.80-5.95 (prev. $5.45-5.65), tariff impact reduced to $60-80M (prev. $80-100M).

**【Q&A Highlights】**
- **MedSurg Growth Drivers**: Specialized sales teams, differentiated brands (e.g., V.A.C. Peel & Place), and new product launches (Tegaderm antimicrobial, sterilization assurance solutions).
- **EPS Bridge**: Q2 beat ($0.30 vs. guidance) driven by sales, margins, and tax. H2 guidance reflects normalized growth (1.5% organic) and tariff mitigation.
- **ERP Implementation**: Europe cutover successful despite challenges; 2026-2027 milestones to reduce separation costs and improve cash flow.
- **Dental Segment**: No market recovery yet, but new products (e.g., 3D-printed attachments) and specialized sales teams driving momentum.
- **P&F Transaction**: Drinking water retention unlocks value; transaction accretes EPS in 2026+ with neutral 2025 impact.


Solventum Corporation (SOLV) Q2 2025 Earnings Call Transcript

- **Strong Q1 Growth**: 4.3% organic sales growth, driven by MedSurg (8.2% Infection Prevention) and Dental Solutions resilience.
- **Tariff Headwinds**: $80-100M impact expected, partially offset by FX neutralization and cost control.
- **Sustainable Momentum**: 2.5% normalized organic growth (excluding order timing), supported by new product launches and commercial execution.
- **Margin Management**: Gross margin expected to stabilize at low end of 20-21% range, with Q2 operating margin above 20%.
- **Cash Flow Focus**: Maintaining $450-550M free cash flow target despite separation costs.


**【CEO Opening Remarks】**
- Q1 2025 organic sales growth of 4.3%, marking 4 consecutive quarters of positive growth.
- Tariffs will create a $80-100M headwind in 2025, but company expects to offset through cost control and mitigation strategies.
- MedSurg segment led by 8.2% growth in Infection Prevention & Surgical Solutions, driven by order timing and new product adoption.
- Dental Solutions segment showed resilience despite market challenges, with strong performance in core restoratives and new product launches.
- HIS segment benefited from strong retention of Revenue Cycle Management software solutions.

**【CFO Financial Commentary】**
- Q1 GAAP net income: $420M; Non-GAAP EPS: $1.34 (vs. guidance of $5.45-5.65 for FY25).
- Gross margin: 55.6% (down 260bps YoY due to 3M supply agreement costs).
- Operating expenses flat QoQ, with savings from restructuring on track.
- Free cash flow: -$80M (sequential payment timing impact).
- FY25 guidance update: Organic sales growth 1.5-2.5% (up 50bps), EPS maintained at $5.45-5.65 despite tariff headwinds.

**【Q&A Highlights】**
- **Sales Growth Sustainability**: CEO emphasizes 2.5% normalized organic growth (excluding order timing), driven by commercial execution improvements and new product launches.
- **Tariff Mitigation**: CFO outlines strategies including USMCA certifications, supply chain optimization, and selective pricing. Impact expected in Q3/Q4 due to 90-day inventory turnover.
- **Dental Segment Performance**: Despite 0.4% organic growth, company outperformed market through innovation in core restoratives and aesthetic solutions.
- **ERP Implementation**: Q2 cutover expected to cause temporary order timing drawdown, with full normalization by Q4.


Solventum Corporation (SOLV) Q1 2025 Earnings Call Transcript

- **Revenue Momentum**: Q4 2.3% organic growth, 3 consecutive quarters of volume improvement, driven by MedSurg and Dental innovation.
- **AI-Driven Growth**: HIS autonomous coding targets 50-90% case automation, reducing costs and errors.
- **2025 Outlook**: 1.5-2.5% normalized sales growth, 20-21% operating margin, and EPS neutral impact from P&F divestiture.
- **M&A Readiness**: Post-P&F sale, 2026+ focus on tuck-in acquisitions in high-growth medtech markets.
- **Risk Management**: Minimal tariff exposure, but cautious on U.S.-China trade uncertainty.

**【CEO Summary Section】**
- Delivered $2.1B in Q4 revenue, up 2.3% organically, driven by volume growth across MedSurg, Dental, and Purification & Filtration segments.
- Advanced Wound Care (V.A.C. Peel and Place) and Dental Solutions (3D-printed attachments) showed strong demand, with capacity expansions underway.
- Health Information Systems (HIS) achieved 1.1% organic growth through AI-driven autonomous coding adoption, targeting 50-90% case automation.
- 2025 guidance: 1-2% organic sales growth (1.5-2.5% normalized), $5.45-$5.65 EPS, and $450M-$550M free cash flow.
- Purification & Filtration divestiture to Thermo Fisher expected to close in H2 2025, with proceeds used to deleverage and enable M&A.

**【CFO Financial Commentary】**
- Q4 gross margin 56.2%, down 100bps vs. prior year due to 3M supply agreement costs.
- Operating expenses up due to public company stand-up costs and growth investments, but restructuring savings to ramp in 2025.
- Free cash flow $805M for FY24, exceeding initial guidance.
- 2025 operating margin expected 20-21%, with headwinds from 3M costs and tailwinds from restructuring.

**【Q&A Key Questions】**
- **Organic Growth by Segment**: MedSurg (+1.8%), Dental (+4.2%), HIS (+1.1%), P&F (+3.5%). All segments benefitting from commercial excellence and new product launches.
- **Free Cash Flow Guidance**: Lower due to separation costs ($130M+ in 2025), but 2026+ savings expected.
- **Tariff Impact**: Minimal exposure (limited China manufacturing), but monitoring fluid U.S.-China trade dynamics.
- **M&A Strategy**: Post-P&F sale, targeting 2026 for tuck-in acquisitions in high-growth medtech areas.
- **SKU Rationalization**: Exiting 5,000 SKUs (8% of portfolio) to simplify supply chain, with 50bps 2025 headwind but long-term margin benefits.

Actual	2.08	1.56	1.64	1.41	1.34	1.69	1.5	1.57
Forecast	1.745	1.505	1.3938	1.3144	1.2111	1.4497	1.4301	1.4948
Surprise	+19.20%	+3.65%	+17.66%	+7.27%	+10.64%	+16.58%	+4.89%	+5.03%

Actual	2.02B	2.08B	2.08B	2.07B	2.07B	2.16B	2.10B	2.00B
Forecast	1.97B	2.05B	2.06B	2.05B	2.02B	2.12B	2.06B	1.96B
Surprise	+2.54%	+1.57%	+1.25%	+1.13%	+2.66%	+1.97%	+1.96%	+1.84%

SOLV

SOLV fundamentals

SOLV Q4 2025 Earnings

Earnings Call

You can ask Aime

SOLV

SOLV fundamentals

SOLV Q4 2025 Earnings

Earnings Call

SOLV Earnings Call Summary for Q4/20254:30 PM on Feb 26, 2026

SOLV Earnings Call Summary for Q3/20254:30 PM on Nov 6, 2025

SOLV Earnings Call Summary for Q2/20254:30 PM on Aug 7, 2025

SOLV Earnings Call Summary for Q1/20254:30 PM on May 8, 2025

SOLV Earnings Call Summary for Q4/20244:30 PM on Feb 27, 2025

You can ask Aime